DFTX Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Definium Therapeutics Inc (DFTX) following the 2026 Q2 hedge fund 13F filings?

As of today, DFTX has moved -13.6% since the 2026 Q2 13F filing date (August 14, 2026), compared to -0.6% for the XLV sector ETF — an outperformance of -13.0%. Since the quarter end (June 30, 2026), DFTX gained -21.7% vs +10.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Definium Therapeutics Inc (DFTX)

351 + Investors. Track Smart Money conviction in DFTX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — DFTX

Based on 360 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 2Q

For 2 consecutive quarters, more hedge funds added DFTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

360 hedge funds hold DFTX right now — the highest count in 0.8 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🟢

More buyers than sellers — 73% buying

268 buying101 selling

Last quarter: 268 funds were net buyers (152 opened a brand new position + 116 added to an existing one). Only 101 were sellers (66 trimmed + 35 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-85 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 237 → 152. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 98% entered in last year

■ 0% conviction (2yr+) ■ 2% medium ■ 98% new

Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Value +279% but shares only +64% — price-driven

Value

+278%

+64%

Last quarter: the total dollar value of institutional holdings rose +279%, but actual share count only changed +64%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🌱

Early stage — 100% of holders entered in last year

■ 0% veterans ■ 0% 1-2yr ■ 100% new

Of 379 current holders: 379 (100%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

🏆

Elite ownership — 47% AUM from top-100 funds

47% from top-100 AUM funds

55 of 352 holders are among the 100 largest funds by AUM, controlling 47% of total institutional value in DFTX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

5.5

out of 10

Moderate Exit Risk

Exit risk score 5.5/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	351	243	44.44%
13F Shares	119M	76M	56.49%
Total Value	$5.30B	$1.43B	269.68%
New Positions	151	237	-86
Increased Positions	118	2	+116
Closed Positions	35	2	+33
Reduced Positions	60	3	+57
Total Calls	15	9	66.67%
Total Puts	12	5	140.0%
PUT/CALL Ratio	0.8	0.56	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

351

243

44.44%

13F Shares

119M

76M

56.49%

Total Value

$5.30B

$1.43B

269.68%

New Positions

151

237

-86

Increased Positions

118

+116

Closed Positions

+33

Reduced Positions

+57

Total Calls

66.67%

Total Puts

140.0%

PUT/CALL Ratio

0.8

0.56

Neutral

Institutional Holders (2026 Q2)

351 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DFTX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 DFTX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Ally Bridge Group (NY) LLC	16.64%	400,000	$18.8M
2	Octagon Capital Advisors LP	12.47%	2,950,000	$138.8M
3	Data Collective IV GP, LLC	6.01%	100,350	$4.7M
4	Commodore Capital LP	5.60%	2,000,000	$94.1M
5	Superstring Capital Management LP	5.59%	188,282	$8.9M
6	Catalio Capital Management, LP	4.97%	562,672	$26.5M
7	Great Point Partners LLC	3.78%	425,000	$20.0M
8	Boxer Capital Management, LLC	3.54%	998,500	$47.0M
9	AWM Investment Company, Inc.	3.20%	784,800	$36.9M
10	Avoro Capital Advisors LLC	3.04%	7,188,888	$338.2M
11	HighVista Strategies LLC	2.60%	242,884	$11.4M
12	Sectoral Asset Management Inc	2.57%	78,310	$3.7M
13	Tetragon Partners GP Ltd	2.13%	286,990	$13.5M
14	Silverarc Capital Management, LLC	1.96%	400,000	$18.8M
15	Deep Track Capital, LP	1.88%	2,750,000	$129.4M
16	Driehaus Capital Management LLC	1.87%	6,845,276	$322.0M
17	Silverback Asset Management LLC	1.50%	294,400	$13.8M
18	Siren, L.L.C.	1.35%	1,419,493	$66.8M
19	Squadron Capital Management LLC	1.24%	85,000	$4.0M
20	Seven Fleet Capital Management LP	1.15%	148,647	$7.0M
21	Fore Capital, LLC	1.11%	80,000	$3.8M
22	Stempoint Capital LP	1.11%	137,124	$6.5M
23	Peak Financial Advisors LLC	1.11%	56,915	$2.7M
24	ArrowMark Colorado Holdings LLC	1.10%	564,069	$26.5M
25	Integral Health Asset Management, LLC	1.02%	550,000	$25.9M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Definium Therapeutics Inc (DFTX)

What does the Smart Money Trend signal show for DFTX?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added DFTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for DFTX?

More buyers than sellers — 73% buying: Last quarter: 268 funds were net buyers (152 opened a brand new position + 116 added to an existing one). Only 101 were sellers (66 trimmed + 35 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for DFTX holders?

Elite ownership — 47% AUM from top-100 funds: 55 of 352 holders are among the 100 largest funds by AUM, controlling 47% of total institutional value in DFTX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held DFTX?

Mostly new holders — 98% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Definium Therapeutics Inc (DFTX) following the 2026 Q2 hedge fund 13F filings?

As of today, DFTX has moved -13.6% since the 2026 Q2 13F filing date (August 14, 2026), compared to -0.6% for the XLV sector ETF — an outperformance of -13.0%. Since the quarter end (June 30, 2026), DFTX has gained -21.7% vs +10.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Definium Therapeutics Inc (DFTX)

Smart Money Signals — DFTX

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

More buyers than sellers — 73% buying

Fewer new buyers each quarter (-85 vs last Q)

Mostly new holders — 98% entered in last year

Value +279% but shares only +64% — price-driven

Early stage — 100% of holders entered in last year

Elite ownership — 47% AUM from top-100 funds

Institutional Sentiment Summary — DFTX

Hedge Fund Ownership: DFTX

Market Analysis: DFTX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: DFTX

Is It Too Late to Buy Definium Therapeutics Inc (DFTX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: DFTX

Statistics: DFTX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Definium Therapeutics Inc (DFTX)

Welcome to 13Foresight!